39 companies

Teva Pharmaceutical Industries

Market Cap: US$37.5b

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

New

TEVA

US$31.82

7D

-8.2%

1Y

98.4%

Arrowhead Pharmaceuticals

Market Cap: US$10.4b

Develops medicines for the treatment of intractable diseases in the United States.

New

ARWR

US$71.91

7D

-17.3%

1Y

307.9%

ImmunityBio

Market Cap: US$8.2b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

New

IBRX

US$7.88

7D

-10.0%

1Y

187.6%

PTC Therapeutics

Market Cap: US$6.7b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

New

PTCT

US$78.06

7D

-12.5%

1Y

63.5%

IDEAYA Biosciences

Market Cap: US$3.4b

A precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

New

IDYA

US$36.65

7D

-9.5%

1Y

71.0%

Tarsus Pharmaceuticals

Market Cap: US$2.6b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

New

TARS

US$56.11

7D

-20.5%

1Y

38.3%

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

New

MLYS

US$27.28

7D

-10.4%

1Y

86.6%

Stoke Therapeutics

Market Cap: US$1.8b

Engages in the development of treatments for severe genetic diseases by upregulating protein expression.

New

STOK

US$29.13

7D

-11.8%

1Y

147.9%

Taysha Gene Therapies

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

New

TSHA

US$5.70

7D

-12.3%

1Y

127.1%

MeiraGTx Holdings

Market Cap: US$1.1b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

New

MGTX

US$12.44

7D

-15.1%

1Y

45.2%

Solid Biosciences

Market Cap: US$956.9m

Develops therapies for neuromuscular and cardiac diseases in the United States.

New

SLDB

US$9.63

7D

-13.6%

1Y

78.7%

Annexon

Market Cap: US$922.4m

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

New

ANNX

US$5.55

7D

-13.7%

1Y

122.0%

Arbutus Biopharma

Market Cap: US$921.5m

A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

New

ABUS

US$4.61

7D

-11.0%

1Y

47.3%

Immix Biopharma

Market Cap: US$748.9m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

New

IMMX

US$10.68

7D

-11.1%

1Y

287.0%

Ironwood Pharmaceuticals

Market Cap: US$693.0m

A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

New

IRWD

US$3.98

7D

-11.0%

1Y

479.3%

Allogene Therapeutics

Market Cap: US$666.1m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

New

ALLO

US$1.85

7D

-14.0%

1Y

49.2%

REGENXBIO

Market Cap: US$659.2m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

New

RGNX

US$12.29

7D

-18.2%

1Y

49.2%

4D Molecular Therapeutics

Market Cap: US$590.7m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

New

FDMT

US$11.70

7D

-8.7%

1Y

181.3%

Sutro Biopharma

Market Cap: US$492.6m

Operates as an oncology company.

STRO

US$27.84

7D

-9.1%

1Y

264.5%

Kyverna Therapeutics

Market Cap: US$472.4m

A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

New

KYTX

US$7.94

7D

-18.0%

1Y

107.9%

Prothena

Market Cap: US$462.3m

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.

New

PRTA

US$8.64

7D

-10.7%

1Y

38.9%

Ovid Therapeutics

Market Cap: US$453.5m

A biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.

New

OVID

US$2.46

7D

-10.9%

1Y

568.5%

Cabaletta Bio

Market Cap: US$450.8m

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

New

CABA

US$2.67

7D

-13.9%

1Y

63.8%

Prelude Therapeutics

Market Cap: US$440.3m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

New

PRLD

US$4.39

7D

-11.7%

1Y

438.7%

Enanta Pharmaceuticals

Market Cap: US$396.6m

A biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.

New

ENTA

US$13.11

7D

-8.1%

1Y

98.9%

Lyell Immunopharma

Market Cap: US$334.4m

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

New

LYEL

US$13.40

7D

-15.8%

1Y

47.3%

Opus Genetics

Market Cap: US$314.6m

A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.

New

IRD

US$3.56

7D

-12.1%

1Y

223.6%

MacroGenics

Market Cap: US$286.0m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.

New

MGNX

US$4.29

7D

-9.7%

1Y

187.9%

ALX Oncology Holdings

Market Cap: US$265.1m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

New

ALXO

US$2.00

7D

-15.3%

1Y

328.7%

Coherus Oncology

Market Cap: US$226.7m

A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

New

CHRS

US$1.45

7D

-13.2%

1Y

70.7%

Whitehawk Therapeutics

Market Cap: US$206.5m

A clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.

New

WHWK

US$3.81

7D

-8.2%

1Y

96.4%

Nkarta

Market Cap: US$199.6m

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

New

NKTX

US$2.65

7D

-21.6%

1Y

45.6%

Canton Strategic Holdings

Market Cap: US$175.1m

Engages in the institutional blockchain adoption and digitization of financial markets in the United States.

New

CNTN

US$2.30

7D

-8.0%

1Y

36.9%

OnKure Therapeutics

Market Cap: US$172.9m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.

New

OKUR

US$4.11

7D

-10.7%

1Y

64.4%

Pyxis Oncology

Market Cap: US$154.6m

A clinical stage company, engages in the development of therapeutics to treat solid tumors.

PYXS

US$2.29

7D

-25.4%

1Y

97.4%

iBio

Market Cap: US$72.0m

A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.

New

IBIO

US$1.44

7D

-9.4%

1Y

98.6%

Page 1 of 2